Trastuzumab deruxtecan
德曲妥珠单抗HER2-directed ADC whose 2026 NRDL payment scope expands from 2 breast cancer settings to 7 indications across breast, gastric/GEJ, and HER2-mutant NSCLC.
China Approval (NMPA)
Approved- Approval Number(s)
- 国药准字SJ20230005
- Initial Approval Date
- Feb 21, 2023
- Notice Published
- Feb 24, 2023
- MAH
- Daiichi Sankyo Europe GmbH (第一三共欧洲公司)
- Approved Scope
- Initial approval for unresectable/metastatic HER2-positive adult breast cancer after ≥1 prior anti-HER2 regimen; subsequently expanded across HER2-low/ultralow BC, gastric/GEJ cancer, and HER2-mutant NSCLC.
National Reimbursement
Announced · Effective Jan 1, 2027- 2026 Edition Entry
- Negotiated #255 · Class B
- Agreement Period
- 2027-01-01 to 2028-12-31
- Payment Standard
- * Confidential (marked with asterisk in NHSA PDF)
- 2026 Payment Scope
- Expanded to 7 indications: (1) ≥2L HER2+ mBC; (2) HER2-low mBC; (3) HR+ HER2-low/ultralow mBC post-ET; (4) Neoadjuvant HER2+ stage II high-risk/III BC seq. THP; (5) ≥3L HER2+ gastric/GEJ; (6) ≥2L HER2+ gastric/GEJ post-trastuzumab; (7) ≥2L HER2 (ERBB2)-mutant NSCLC.
- 限:1.HER2阳性不可切除/转移性乳腺癌(≥1线抗HER2后);2.HER2低表达不可切除/转移性乳腺癌(化疗后);3.HR阳性HER2低表达或HER2超低表达(IHC 0伴细胞膜染色)乳腺癌(内分泌治疗进展后单药);4.序贯THP用于HER2阳性Ⅱ期(高危)或Ⅲ期乳腺癌新辅助治疗;5.HER2阳性局部晚期/转移性胃或GEJ腺癌(≥2线后);6.HER2阳性局部晚期/转移性胃或GEJ腺癌(≥1线含曲妥珠单抗方案后);7.HER2(ERBB2)激活突变不可切除/转移性NSCLC(≥1线系统治疗后)。
Commercial Insurance List
Not ListedNot listed in the 2025 or 2026 NHSA Commercial Health Insurance Innovative Drug List.
2025 vs 2026 NRDL Payment Scope Comparison
Restricted to 2 breast cancer settings: (1) Unresectable/metastatic HER2+ breast cancer after ≥1 prior anti-HER2 therapy; (2) Unresectable/metastatic HER2-low (IHC 1+ or 2+/ISH-) breast cancer after prior systemic therapy or ≤6-month adjuvant recurrence.
限:1.既往接受过一种或一种以上抗HER2药物治疗的不可切除或转移性HER2阳性成人乳腺癌患者;2.既往在转移性疾病阶段接受过至少一种系统治疗的,或在辅助化疗期间或完成辅助化疗之后6个月内复发的,不可切除或转移性HER2低表达(IHC 1+或IHC 2+/ISH-)成人乳腺癌患者。
Expanded to 7 indications: (1) ≥2L HER2+ mBC; (2) HER2-low mBC; (3) HR+ HER2-low/ultralow mBC post-ET; (4) Neoadjuvant HER2+ stage II high-risk/III BC seq. THP; (5) ≥3L HER2+ gastric/GEJ; (6) ≥2L HER2+ gastric/GEJ post-trastuzumab; (7) ≥2L HER2 (ERBB2)-mutant NSCLC.
限:1.HER2阳性不可切除/转移性乳腺癌(≥1线抗HER2后);2.HER2低表达不可切除/转移性乳腺癌(化疗后);3.HR阳性HER2低表达或HER2超低表达(IHC 0伴细胞膜染色)乳腺癌(内分泌治疗进展后单药);4.序贯THP用于HER2阳性Ⅱ期(高危)或Ⅲ期乳腺癌新辅助治疗;5.HER2阳性局部晚期/转移性胃或GEJ腺癌(≥2线后);6.HER2阳性局部晚期/转移性胃或GEJ腺癌(≥1线含曲妥珠单抗方案后);7.HER2(ERBB2)激活突变不可切除/转移性NSCLC(≥1线系统治疗后)。
Approved Products, Dosage Forms & Approval Numbers
1 verified NMPA record| Approval No. | Dosage Form & Strength | Event & Scope | Approval / Notice Date | MAH & Source |
|---|---|---|---|---|
| 国药准字SJ20230005 | Powder for Injection (注射剂) 100mg/瓶 | Initial Approval Initial approval for unresectable/metastatic HER2-positive adult breast cancer after ≥1 prior anti-HER2 regimen; subsequently expanded across HER2-low/ultralow BC, gastric/GEJ cancer, and HER2-mutant NSCLC. 首发获批用于既往接受过一种或一种以上抗HER2药物治疗的不可切除或转移性HER2阳性成人乳腺癌患者;后续扩展至HER2低/超低表达乳腺癌、胃癌及HER2突变NSCLC。 | Approved: 2023-02-21 Published: 2023-02-24 | Daiichi Sankyo Europe GmbH |
Change Timeline
- (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026
2026 NRDL · Payment Scope Updated
Expanded from 2 breast cancer settings in 2025 (#228) to 7 indications in 2026 (#255), adding HR+ HER2-low/ultralow BC, neoadjuvant HER2+ BC, 2L/3L+ HER2+ gastric/GEJ, and HER2-mutant NSCLC.
Chinese original: 支付范围由2025版2项扩增至7项,新增HR+ HER2低/超低表达乳腺癌、HER2+乳腺癌新辅助、HER2+胃/GEJ腺癌(二线及三线以上)及HER2突变NSCLC。
NHSA · PDF p.142Verified 2026-11-20 - (2023-02-21)NMPA Approval· Notice published: Feb 24, 2023
NMPA Initial Marketing Approval (国药准字SJ20230005 · 100mg/瓶)
Initial approval for unresectable/metastatic HER2-positive adult breast cancer after ≥1 prior anti-HER2 regimen; subsequently expanded across HER2-low/ultralow BC, gastric/GEJ cancer, and HER2-mutant NSCLC.
Chinese original: 首发获批用于既往接受过一种或一种以上抗HER2药物治疗的不可切除或转移性HER2阳性成人乳腺癌患者;后续扩展至HER2低/超低表达乳腺癌、胃癌及HER2突变NSCLC。
NMPA · NMPA Registration SJ20230005Verified 2026-11-21
Verified Names & Aliases
Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.
Primary Sources for This Record
- NHSAPublished 2026-11-14国家基本医疗保险、生育保险和工伤保险药品目录(2026年)Retrieved 2026-11-20
- NHSAPublished 2025-12-07国家基本医疗保险、生育保险和工伤保险药品目录(2025年)Retrieved 2026-11-20 · 医保发〔2025〕33号附件
- NMPA国家药品监督管理局政务服务门户与药品查询Retrieved 2026-11-20
- WHO世界卫生组织国际非专利药名(INN)指南Retrieved 2026-11-20